A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
A Phase III Open-label, Randomised, Multicentre Study Comparing AZD0120, a Dual-Targeting Autologous Chimeric Antigen Receptor T-cell (CART) Therapy Directed Against BCMA and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma.
- Relapsed Refractory Multiple Myeloma
At a glance
- Phase
- Phase 3
- Study type
- Interventional
- Sponsor
- AstraZeneca
- Enrolment target
- 508
- Started
- 23 February 2026
- Main results due
- 14 June 2028
- Study sites
- 143
- Registry updated
- 29 September 2026
Can you take part?
- Aged 18 years and over.
- Open to any sex.
- You need the condition being studied — healthy volunteers are not accepted.
These are the headline rules only. Every study has a longer list, and whether you are eligible is decided by the research team at the site — never by this page.
Read the full eligibility criteria
Inclusion Criteria: * Age ≥ 18 years * Documented diagnosis of multiple myeloma according to the IMWG diagnostic criteria * Documented evidence of measurable disease: 1. Serum M-protein level ≥ 1 g/dL 2. Urine M-protein level ≥ 200 mg/24h 3. Serum immunoglobulin free light chain ≥ 10 mg/dL (100 mg/L) and abnormal serum immunoglobulin kappa lambda free light chain ratio * Documented evidence of PD by IMWG 2016 criteria based on investigator's determination during or after the most recent line of therapy. Participants with only 1 prior line of therapy must have progressed within 47 months of a stem cell transplant, or if not transplanted, then within 42 months of starting initial therapy * Received 1 to 3 lines of prior therapy including an IMiD and either a PI or a CD38 antibody. Participant must have undergone at least 2 complete cycles of treatment for each line of therapy, unless PD was the best response to the line of therapy * Eligible to receive at least one of the standard regimens (DKd, PVd, DPd, or Kd) as determined by the Investigator. * ECOG performance status score of 0 to 1 * Adequate hematology and chemistry laboratory values: 1. Haemoglobin ≥ 8.0 g/dL 2. Absolute neutrophil count ≥ 1 × 10\^9/L (1000 per mm3) 3. Platelet count ≥ 75 × 10\^9/L (75000 per mm3) in participants with \< 50% of bone marrow nucleated cells are plasma cells or ≥ 50 × 10\^9/L (50000 per mm3) in participants with ≥ 50% of bone marrow nucleated cells are plasma cells 4. Absolute lymphocyte count ≥ 300/µL (0.3 × 109/L) 5. Total bilirubin ≤ 1.5 × ULN in the absence of Gilbert's syndrome or ≤ 3 × ULN if the participant has Gilbert's syndrome. AST and ALT≤ 3.0 × ULN. CrCl by Cockcroft and Gault method ≥ 30 mL/minute Exclusion Criteria: * Known active, or prior history of CNS involvement or exhibits clinical signs of meningeal involvement of MM. * Primary amyloidosis, active plasma cell leukaemia, Waldenstrom macroglobulinemia or Polyneuropathy Organomegaly Endocrinopathy M-protein and Skin (POEMS) syndrome. * Participants with primary refractory MM (failed to generate at least a minimal response to any prior therapy) * Significant neurological or psychiatric condition * Significant medical condition that places the participant at an unacceptable risk for treatment-related complications * Previously received any prior BCMA-targeted treatment * Previously received CAR-T or CAR-NK therapy directed at any target * Previously received T-cell engager therapy directed at any target * Previously received allogeneic stem cell transplantation at any time during prior therapy or received autologous stem cell transplantation within 12 weeks of randomization
What this study is about
In the sponsor’s own words, from the registry.
This is a randomised, multicentre, controlled, open-label, Phase III global study comparing the efficacy and safety of AZD0120 versus standard regimens (DKd \[daratumumab, carfilzomib, and dexamethasone\], DPd \[daratumumab, pomalidomide, and dexamethasone\], PVd \[pomalidomide, bortezomib and dexamethasone\], or Kd \[carfilzomib and dexamethasone\]) in participants with RRMM.
Study sites(143)
Research Site
Gilbert, Arizona, United States
Not yet recruiting
Research Site
Phoenix, Arizona, United States
Withdrawn
Research Site
Tucson, Arizona, United States
Not yet recruiting
Research Site
La Jolla, California, United States
Withdrawn
Research Site
Sacramento, California, United States
Not yet recruiting
Research Site
Santa Monica, California, United States
Not yet recruiting
Research Site
Denver, Colorado, United States
Recruiting
Research Site
New Haven, Connecticut, United States
Recruiting
Research Site
Washington D.C., District of Columbia, United States
Not yet recruiting
Research Site
Coral Gables, Florida, United States
Withdrawn
Research Site
Tampa, Florida, United States
Not yet recruiting
Research Site
Atlanta, Georgia, United States
Recruiting
Research Site
Chicago, Illinois, United States
Not yet recruiting
Research Site
Park Ridge, Illinois, United States
Not yet recruiting
Research Site
Iowa City, Iowa, United States
Withdrawn
Research Site
Kansas City, Kansas, United States
Not yet recruiting
Research Site
Louisville, Kentucky, United States
Recruiting
Research Site
Boston, Massachusetts, United States
Not yet recruiting
Research Site
Boston, Massachusetts, United States
Not yet recruiting
Research Site
Boston, Massachusetts, United States
Withdrawn
Research Site
Detroit, Michigan, United States
Withdrawn
Research Site
Detroit, Michigan, United States
Withdrawn
Research Site
Rochester, Minnesota, United States
Withdrawn
Research Site
Albany, New York, United States
Not yet recruiting
Research Site
New York, New York, United States
Withdrawn
Research Site
New York, New York, United States
Recruiting
Research Site
New York, New York, United States
Withdrawn
Research Site
New York, New York, United States
Recruiting
Research Site
Rochester, New York, United States
Withdrawn
Research Site
The Bronx, New York, United States
Withdrawn
Research Site
Chapel Hill, North Carolina, United States
Not yet recruiting
Research Site
Charlotte, North Carolina, United States
Not yet recruiting
Research Site
Charlotte, North Carolina, United States
Recruiting
Research Site
Winston-Salem, North Carolina, United States
Recruiting
Research Site
Winston-Salem, North Carolina, United States
Not yet recruiting
Research Site
Cincinnati, Ohio, United States
Not yet recruiting
Research Site
Cleveland, Ohio, United States
Not yet recruiting
Research Site
Portland, Oregon, United States
Not yet recruiting
Research Site
Charleston, South Carolina, United States
Withdrawn
Research Site
Nashville, Tennessee, United States
Recruiting
Research Site
Austin, Texas, United States
Recruiting
Research Site
Dallas, Texas, United States
Not yet recruiting
Research Site
Houston, Texas, United States
Recruiting
Research Site
Salt Lake City, Utah, United States
Not yet recruiting
Research Site
Charlottesville, Virginia, United States
Withdrawn
Research Site
Gainesville, Virginia, United States
Not yet recruiting
Research Site
Richmond, Virginia, United States
Withdrawn
Research Site
Puyallup, Washington, United States
Not yet recruiting
Research Site
Seattle, Washington, United States
Recruiting
Research Site
Madison, Wisconsin, United States
Not yet recruiting
Research Site
Milwaukee, Wisconsin, United States
Recruiting
Research Site
Camperdown, Australia
Recruiting
Research Site
Darlinghurst, Australia
Recruiting
Research Site
Fitzroy, Australia
Recruiting
Research Site
Liverpool, Australia
Not yet recruiting
Research Site
Melbourne, Australia
Recruiting
Research Site
Melbourne, Australia
Recruiting
Research Site
Murdoch, Australia
Not yet recruiting
Research Site
Salvador, Brazil
Recruiting
Research Site
São Paulo, Brazil
Recruiting
Showing 60 of 143 sites — filter to narrow it down. 40 of the 143 sites on this study are recruiting right now — a site can stop enrolling while the study as a whole is still open.
Source: ClinicalTrials.gov record NCT07391657. Trialion does not run this study, is not paid to refer anyone to it, and cannot enrol you. Eligibility is always decided by the research team at the site.
Not the right study?
Answer three questions and see the studies recruiting near you, in plain language.
Find a study for me